Login to Your Account



Celator enrolls phase III study of CPX-351 early

By Marie Powers
Staff Writer

Monday, October 27, 2014

Celator Pharmaceuticals Inc., which advanced lead compound CPX-351 into a pivotal phase III study in AML, hit its target enrollment of 300 patients ahead of schedule.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription